Navigation Links
Reportlinker Adds Threats to Avastin - Targeting the VEGF Pathway
Date:8/31/2010

NEW YORK, Aug. 31 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Threats to Avastin - Targeting the VEGF Pathway http://www.reportlinker.com/p0196624/Threats-to-Avastin---Targeting-the-VEGF-Pathway-.html

Avastin is set to become the most successful cancer treatment to date and one of the leading drugs with sales likely to exceed US$9 billion by 2015.

Since its launch in 2004, Avastin has achieved strong growth culminating in sales of US$5,731 million (SFr 6.2 billion) in 2009. Not only is Avastin now Roche's top-selling oncology product, ahead of both MabThera/Rituxan (rituximab) and Herceptin (trastuzumab), but its sales exceed those of every other cancer product on the market.

In 2009, solid growth was seen across all markets, driven by continued uptake in colorectal cancer (CRC), breast cancer (BC) and non-small cell lung cancer (NSCLC). In the US, metastatic BC was the main growth driver, helped by launches for the new indications of glioblastoma and renal cell carcinoma (RCC). Strong growth was seen in the EU in all indications. In the Japanese market, Avastin sales growth was particularly strong with continued substantial uptake in CRC, enhanced by its recent approval for NSCLC.

While its first-to-market status and Roche's experience in the oncology sector have provided a sound basis for growth, a number of related angiogenesis products have been launched and many more are on the horizon. What threat do they present to Avastin's status and when will their impact be felt?

The current market

Avastin is the only product that currently directly inhibits VEGF. Competing products take a different approach. Bayer/Onyx Nexavar, Pfizer's Sutent and GSK's Votrient/Armala are all multi-kinase inhibitors and Pfizer's Torisel and Novartis' Afinitor are mTOR (kinase) inhibitors.

Looking forward...

Drugs with novel mechanisms of inhibiting angiogenesis are beginning to emerge in company pipelines. Espicom has identified 13 major projects in Phase III development, with a further 10 in Phase II. Novel agents include:

Enzastaurin: A novel agent that acts through inhibition of protein kinase C and has been found to suppress tumour growth through multiple mechanisms, such as the direct suppression of tumour cell proliferation.

Panobinostat: This pan-histone deacetylase inhibitor targets multiple oncogenic pathways, including angiogenesis.

PF-02341066: This is a selective ATP-competitive small-molecule inhibitor of both c-Met/hepatocyte growth factor receptor and anaplastic lymphoma kinase tyrosine kinases and their oncogenic variants.

With this report you will...

Understand Avastin's unique position in the oncology market

Evaluate its strengths and weaknesses relative to other VEGF-targeting products

Gain insight into the prevalence of cancers in Avastin's therapeutic window

Review the merits of 21 late-phase development prospects with Espicom's unique 5-point competitive assessment

Know the launch timeframe for up and coming products

Estimate future revenues with 5-year forecasts for more than 20 launched and late-phase products

Just some of the approaches being used by products in this report

VEGFr-1, -2 and -3 tyrosine kinase inhibitors

VEGF Trap

MET & RET inhibitors

PDGFr inhibitors

HDAC inhibitors

Questions answered by the report include...

Which other products in the pipeline mirror Avastin's therapeutic approach?

What are the extension indications Avastin is expected to secure to 2016?

In 2012, five products targeting the VEGF pathway are expected to launch – what are they and who are the developers?

Why is Amgen/Takeda's motesanib/AMG 706 expected to achieve revenues in excess of US$1 billion by 2014?

EXECUTIVE SUMMARY

Introduction

Angiogenesis and the Role of VEGF

Angiogenesis Inhibitors

Avastin

Avastin's Place Within the Market

The Secret to Avastin's Success

Opportunities for Avastin

Threats to Avastin

Angiogenesis Inhibitors under Development

Other Areas of Research

Shape of the Future; Sales Forecasts to 2015

Competitor Ratio Analysis

Competitor Ratio Analysis Criteria

Summary

Avastin

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Launched Competitors

Afinitor

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Armala/Votrient

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Nexavar

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Sutent

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Torisel

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Phase III Competitors

Aflibercept

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Axitinib

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Brivanib

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Enzastaurin

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Midostaurin

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Motesanib

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Panobinostat

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition Within the Market-place

Forecast

Competitor Ratio Analysis

PF-02341066

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Ramucirumab

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Recentin

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition Within the Market-place

Forecast

Competitor Ratio Analysis

Vargatef

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition Within the Market-place

Forecast

Competitor Ratio Analysis

XL184

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

Zactima

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition Within the Market-place

Forecast

Competitor Ratio Analysis

Phase II Competitors

Angicept

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Competitor Ratio Analysis

ARQ 197

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Competitor Ratio Analysis

Foretinib

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Competitor Ratio Analysis

Linifanib

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Competitor Ratio Analysis

MGCD265

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Competitor Ratio Analysis

Telatinib

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Competitor Ratio Analysis

Tivozanib

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Forecast

Competitor Ratio Analysis

TSU-68

Mode of Action

Current Status

Proof of Concept/Clinical Data

Development Risks

Company Expertise

Competition within the Market-place

Competitor Ratio Analysis

Others

Apatinib

SU14813

Phase I Competitors

ALN-VSP

CEP-11981

CYC116

E7080

IMC-18F1

OSI-930

PF-4856884

APPEND IX 1: PHASE TRANSITION PROBABILITY

APPEND IX 2: GLOSSARY

APPEND IX 3: BIBLIOGRAPHY

Journals

Other Sources

List of Tables

Comparison of Launched Agents Targeting the VEGF Pathway

Avastin Sales and Launches (2004-2009)

Selected Clinical Trial Survival Results

Estimated Major New Avastin Launches

Selected Anti-Angiogenesis Agents Under Development

Timeline of Phase III Anti-Angiogenesis Development Projects

Molecular Targets for Avastin Competitors

Sales Forecasts (2008-2015)

Key Drugs Analysed

Competitive Scores and Sales Scores

Avastin Sales by Company

Avastin Sales by Indication

Afinitor Sales by Indication

Armala/Votrient Sales by Indication

Nexavar Sales by Indication

Sutent Sales by Indication

Torisel Sales by Indication

Afilibercept Sales by Indication

Axitinib Treatment-Related Adverse Events

Axitinib Sales by Indication

Brivanib Sales by Indication

Enzastaurin Total Sales

Recentin Sales by Indication

Motesanib Sales by Company

Panobinostat Sales by Indication

PF-02341066 Sales by Indication

Ramucirumab Sales by Indication

Recentin Sales by Indication

Vargatef Sales by Indication

XL184 Sales by Indication

Zactima Total Sales

Tivozanib Sales by Indication

Probability of Launch

List of Charts

Angiogenesis is the Formation of New Blood Vessels

Selected Agents Targeting the VEGF Pathway

Oncology Therapy Area Split (2008)

Sales of Targeted Therapies (2008)

Sales of Agents Targeting the VEGF Pathway (2008)

Avastin Geographical Sales (2009)

Avastin Sales (2004-2009)

Relative Proportions of Cancer Indications (2008)

Incidence of Major Cancer Indications (2008 and 2015)

Incidence and Mortality Comparisons (2008)

Sales of VEGF Pathway Inhibitors (2015)

Competitor Ratio Analysis Scores by Product

Analysis of Products Based on Delivery (2015)

Analysis of Products Based on Company (2015)

Avastin Mode of Action

Sales of Avastin by Company (2008-2015)

Avastin Sales by Indication, 2008

Avastin Sales by Indication, 2015

Afinitor Mode of Action

Afinitor Total Sales (2008-2015)

Votrient/Armala Total Sales (2009-2015)

Votrient/Armala Sales by Indication, 2015

Nexavar Dual Mode of Action

Nexavar Total Sales (2008-2015)

Nexavar Sales by Indication, 2008

Nexavar Sales by Indication, 2015

Sutent Mode of Action

Sutent Total Sales (2008-2015)

Sutent Sales by Indication, 2008

Sutent Sales by Indication, 2015

Torisel Mode of Action

Torisel Total Sales (2008-2015)

Torisel Sales by Indication (2015)

Aflibercept Total Sales (2011-2015)

Aflibercept Sales by Indication, 2012

Aflibercept Sales by Indication, 2015

Axitinib Total Sales (2012-2015)

Brivanib Total Sales (2012-2015)

Enzastaurin Total Sales (2014-2016)

Midostaurin Mode of Action

Recentin Total Sales (2011-2015)

Motesanib Total Sales (2010-2015)

Panobinostat Mode of Action

Panobinostat Total Sales (2011-2015)

PF-02341066 Total Sales (2013-2015)

Ramucirumab Total Sales (2013-2015)

Cediranib Mechanism Of Action

Recentin Total Sales (2011-2015)

Vargatef Mode of Action

Vargatef Total Sales (2013-2015)

XL184 Total Sales (2012-2015)

Zactima Total Sales (2011-2015)

Tivozanib Total Sales (2013-2015)

To order this report:Drug and Medication Industry: Threats to Avastin - Targeting the VEGF Pathway Drug and Medication Business News

More Market Research Report

Check our Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.com US: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds The Outlook for Pharmaceuticals In The Middle East And North Africa To 2015
2. Reportlinker Adds Epigenetics: Current and future applications that are driving novel drug discovery
3. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
4. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
5. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
6. Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets
7. Reportlinker Adds Production and Market of Xylose in China
8. Reportlinker Adds Advances in Large Scale BioManufacturing and Scale-Up Production, 2nd ED
9. Reportlinker Adds European Markets for Small Joint Reconstructive Devices 2010 (15 Countries)
10. Reportlinker Adds Japanese Market for Small Joint Reconstructive Devices 2010
11. Reportlinker Adds Effective Social Media Marketing Strategies for Pharmaceutical Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... 23, 2016 According to ... Development, Growth and Demand Forecast to 2022 - ... by Application (Drug Discovery and Development, Proteomics, Clinical ... Life Science and Biotechnology, Academic and Research Institute, ... the global mass spectrometry market was ...
(Date:5/23/2016)... , May 23, 2016 Gamida ... the treatment of cancer and orphan genetic diseases, announced ... to $4.4 million from the Israel Innovation Authority (formerly ... Ministry of Economy and Industry. The mission of the ... in various industries, including science and technology, while stimulating ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... 24, 2016 , ... BTC Media, a leading digital currency ... to be held in Nashville, Tennessee on September 7, 2016. , The conference ... the event will host teams from around the world, competing to build the ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... debuted a new corporate identity and website at its “Transforming Outcomes” User Conference ... other marketing enhancements reflect i2i’s ongoing success to set the market standard for ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... at Sentara Northern Virginia Medical Center located in Woodbridge, VA. The project ... services into a single site. , The new 2 story building houses the ...
(Date:5/24/2016)... , ... (PRWEB) May ... three new members of its Advisory Board. Joining the Grow ... Kusch. “All three of them embody the mission of our organization ... very fortunate to have them as we continue to expand our ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report reveals that ... access to trusted resources, both in face-to-face interactions and online. In “Heard, Not Judged ... concluded that the creative use of mobile digital devices can be an effective tool ...
Breaking Medicine News(10 mins):